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Background: Right heart dysfunction is a major cause for early morbidity and mor-
tality after heart transplantation. Experiments were designed to evaluate the influ-
ence of the calcium-desensitizing drug 2,3-butanedione 2-monoxime (BDM) on
right heart function in a porcine model of heart transplantation.
Methods: Donor hearts of domestic pigs were arrested with BDM in Krebs solution
(n = 7) and with BDM in Bretschneider’s histidine-tryptophan-ketoglutarate (HTK)
solution (n = 6). There were 2 control groups: University of Wisconsin (UW, n = 6) and
HTK (n = 6). An isovolumic model was used in which the right ventricular volume was
precisely controlled in vivo with an intracavitary high-compliance balloon. After 4
hours of ischemia, hearts were transplanted into recipients. After 1 and 2 hours of
reperfusion, the right ventricular balloon volume was increased in 10-mL increments
until right ventricular failure occurred and the developed pressures were recorded.
Results: Maximal right ventricular developed pressures were significantly different
after 2 hours of reperfusion (UW: 35 ± 13 mm Hg; HTK: 47 ± 8 mm Hg;
Krebs+BDM: 49 ± 9 mm Hg; HTK+BDM: 50 ± 6 mm Hg; P = .04). Hearts sub-
jected to BDM could be loaded with a significantly increased volume after 1 hour
and after 2 hours (UW: 57 ± 10 mL vs HTK: 43 ± 8 mL vs Krebs+BDM: 70 ± 10
mL vs HTK+BDM: 67 ± 15 mL; P = .002). Postischemic right ventricular end-
diastolic compliance was significantly increased in groups treated with BDM after
1 hour (P = .02) and after 2 hours (P = .039).
Conclusions: The drug BDM significantly improves right ventricular function in a
heart transplantation model. The increase in volume load and developed right ven-
tricular pressure achieved by BDM application would translate into a decreased risk
of right ventricular failure after clinical transplantation. 
Right ventricular (RV) dysfunction remains a common and poten-tially severe complication after heart and combined heart-lungtransplantation.1,2 Ischemia-reperfusion injury, incurred duringorgan harvest, distant procurement, and subsequent reperfusion, isthe principal underlying cause. In recent years, new drugs haveexperimentally shown the potential to further improve myocardial
protection, which remains based on clinically well-proven crystalloid solutions.
We3 previously obtained beneficial results from the application of a C1-esterase
inhibitor during reperfusion in a porcine heart transplantation model. A promising
substance that has been suggested as an additive to cardioplegic solutions is 2,3-
butanedione 2-monoxime (BDM).4
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BDM is an effective, fast-acting, and fully reversible
inhibitor of cardiac and skeletal muscle contraction in
man.5 The drug has been claimed to counteract ischemia-
reperfusion injury when added to cardioplegic solutions in
various isolated heart preparations in small animals with a
focus on left ventricular (LV) functional recovery.6-8 Its use
during initial reperfusion in a Langendorff preparation also
gave improved myocardial function; however, the problem
of systemic effects of the drug remains unaddressed.9 As a
cardioplegic adjunct, no systemic effects have to be antici-
pated. For investigation of its additive protective properties,
we used our porcine isovolumic right heart transplantation
model, which allowed total control of RV function after
transplantation under conditions of constant, controlled LV
hemodynamics.3 Our study investigated whether the RV can
benefit from the protective effects of BDM-enhanced
cardioplegia under circumstances mimicking the scenario
of clinical heart transplantation. Therefore, we added
BDM to the clinical standard heart preservation solution,
Bretschneider’s HTK solution, and compared it with HTK
alone as well as with an additional control group using
another clinical standard heart preservation solution,
University of Wisconsin (UW) solution. To test BDM inde-
pendently without the various cardioprotective adjuncts
included in HTK solution, we set up a group in which BDM
was added to Krebs-Henseleit buffer, which is not cardio-
plegic itself. 
Methods
Animal Preparation
In 25 Landrace pigs (27.0 ± 3.8 kg) anesthesia was induced with
azaperone (5 mg/kg, given intramuscularly), atropine (0.5 mg total
dose, given intramuscularly), and thiopental sodium (15 mg/kg,
given intravenously). Animals were intubated and underwent
mechanical ventilation with an inspired oxygen fraction of 0.5. All
animals received humane care in compliance with the German ani-
mal protection legislation, the “Principles of Laboratory Animal
Care,” and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal
Resources, National Research Council, and published by the
National Academy Press, revised 1996.
Donor Heart Preparation
After median sternotomy the pericardium was opened and the
superior and inferior venae cavae and the pulmonary artery were
encircled with tapes. Heparin (300 IU/kg) was administered intra-
venously, and the cardioplegia cannula was secured with a purse-
string suture in the ascending aorta. After a 10-minute stabilization
phase, the inferior vena cava was transected, the left atrial
appendage cut, and the ascending aorta crossclamped after ligation
of the superior vena cava. Cardioplegic solution was then admin-
istered (1000 mL at a perfusion pressure of 40 mm Hg and a tem-
perature of 4°C). 
Four experimental groups were designed. Two control groups
received either UW or Bretschneider’s HTK solution as the car-
dioplegic solution. One group received BDM in Krebs-Henseleit
buffer (30 mmol/L),10,11 and one group received BDM in HTK
solution (30 mmol/L). The solutions were of the following com-
positions:
UW solution (mmol/L) 30 Na+, 125 K+, 5 MgSO4, 25 phos-
phate, 100 lactobionate, 30 raffinose, 5 adenosine, 1 allopurinol, 3
glutathione, and 50 g/L pentastarch (ViaSpan, Belzer UW; Du
Pont Pharma, Bad Homburg, Germany).
HTK solution (mmol/L): 15.0 NaCl, 9.0 KCl, 1.0 potassium
hydrogen-2-ketoglutarate, 4.0 MgCl2, 180.0 histidine, 2.0 trypto-
phan, 30.0 mannitol, and 0.015 CaCl2 (Custodiol; Dr F. Köhler
Chemie, Alsbach-Hähnlein, Germany).
Krebs+BDM (mmol/L): 118.3 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2
KH2PO4, 25.0 NaHCO3, 2.5 CaCl2, and 11.1 glucose supple-
mented with 30 mmol/L BDM (Sigma Chemical Co, St Louis,
Mo).
HTK+BDM: 30 mmol/L BDM was added to HTK solution as
described above. 
Additionally, the hearts were topically cooled with slushed ice.
After completion of cardioplegia, hearts were excised according to
the standard technique and placed on slushed ice consisting of
physiologic saline solution. So that RV volume could be precisely
controlled in vivo, an isovolumic model was used in which RV
volume was regulated with an intracavitary balloon. A high-com-
pliance latex balloon, connected to a 2-cm–diameter polyurethane
tube (Figure 1), was inserted into the RV through the transected
pulmonary artery. The tricuspid valve was closed by a doubled
running suture to prevent balloon herniation and thus provide
absolute volume control in this model. So that the balloon could
fill the entire RV cavity and conform maximally to its internal con-
tour, the tricuspid valve chordae tendineae were cut. A 14-gauge
cannula was inserted into the RV apex for drainage of thebesian
venous blood. Measured amounts of saline solution were added or
withdrawn through a port at the end of the tubing. 
Figure 1. RV balloon system with polyurethane tubing and pres-
sure transducer.
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Recipient Preparation
In 25 Landrace pigs (37 ± 4.9 kg) anesthesia and ventilation were
induced as described above. Mean animal weights did not differ
significantly among groups (Table 1). The mean body weight of
recipient animals was chosen 10 kg heavier than that of donor
animals for technical ease of subsequent transplantation.
Furthermore, pilot studies revealed superior hemodynamic stabil-
ity in heavier recipients. Maintenance anesthesia was administered
intravenously as a continuous infusion of thiopental sodium (5 mg
· kg–1 · h–1) and fentanyl (1 µg · kg–1 · h–1). A carotid artery
catheter was used for monitoring systemic arterial pressure. After
median sternotomy and intravenous administration of a 300-IU/kg
dose of heparin, total cardiopulmonary bypass was implemented
via bicaval venous and bifemoral arterial cannulas. Animals were
kept normothermic. 
Transplantation
Total ischemic time of the hearts was 4 hours (including trans-
plantation). After the recipient hearts were excised, donor hearts
were transplanted with left atrial and aortic anastomoses created
with 4-0 polypropylene running suture. After deairing, the aortic
crossclamp was removed and the hearts were defibrillated and
paced at a constant rate of 120 beats/min. 
In this model, the RV was isolated from the circulation by com-
plete drainage of systemic venous return and coronary sinus efflu-
ent to a pump-oxygenator. Oxygenated blood was returned to the
systemic arterial circulation via the femoral arteries. The coronary
arteries remained directly perfused from the ascending aorta.
Thirty minutes after the crossclamp was opened, an additional
arterial line from the extracorporeal circulation circuit was
inserted into the left atrium. By means of this technique, cardiac
output from the left side of the heart could be controlled by pump-
ing blood into the left atrium at a constant flow rate of 200
mL/min. Hence, a possible volume-related influence of LV func-
tion on RV performance could be avoided. Mean arterial pressure
was kept constant at 60 mm Hg by adjustment of heart-lung
machine flow. No drug therapy was necessary. Pump flow rates
did not differ among groups.
Experimental Protocol
After transplantation, hearts were reperfused for 1 hour, and there-
after the RV balloon volume was increased by 10-mL increments
until RV failure occurred. The point of RV failure was defined as
a decrease in RV developed pressure, which occurred with the
final administered RV balloon volume increment. RV developed
pressure was defined as Psystole – Pdiastole – Pcompliance. The record-
ings were repeated after 2 hours of reperfusion. Left heart hemo-
dynamics were kept constant under the conditions described
above. The latex balloon-tubing system may influence measured
RV pressure by balloon compliance (Pcompliance). Therefore, the
compliance of the RV balloon and tubing system was evaluated
before each experiment with RV balloon volumes from 0 to 100
mL. At maximum volume, a balloon compliance of 8 mm Hg was
obtained. The compliance relationship was linear over the range of
balloon volumes used. The compliance test was performed for
each balloon used and yielded identical curves. As previously
described, the result was used to correct measured values for
developed RV pressure.12 RV developed pressure and rate of RV
pressure rise (RV dP/dt) were measured via a pressure transducer
(Micron miniature transducer MP 15, volume displacement: 9 ×
10–5 mm3/mm Hg; Micron Instruments, Simi Valley, Calif)
attached to a separate port at the polyurethane tubing on the RV
balloon-tubing system. The RV cavity balloon volume was defined
as the total volume in the balloon-tubing system minus the volume
in the tubing. RV diastolic compliance was calculated from the RV
balloon volume in milliliters and the end-diastolic RV pressure in
millimeters of mercury. Systemic blood pressure was measured
with a fluid-filled catheter in the right common carotid artery.
Experiments were terminated 2 hours after the second hemody-
namic measurement by an overdose of thiopental. The trans-
planted hearts were removed and the RV and LV free wall and the
interventricular septum were separated and weighed.
Blood samples for measurement of serum lactate and troponin-T
levels, creatine kinase (CK) activity, and CK-MB concentration were
drawn at the following intervals: after insertion of a carotid artery
catheter and after 10, 60, and 120 minutes of reperfusion. Samples
after 10, 60, and 120 minutes were collected from the coronary sinus
to obtain exact measurements of myocardial marker release. Lactate
and troponin-T serum levels, CK activity, and the CK-MB concen-
tration were determined by standard laboratory tests.
Statistical Analysis
Data are expressed as mean ± standard deviation. The paired
Student t test was used to determine statistical significance of intra-
group comparisons. One-way analysis of variance (ANOVA) was
used to compare means of groups. If a significant F value was
obtained, a Bonferroni post hoc analysis was used to identify dif-
ferences among means while controlling for multiple comparisons.
TABLE 1. Morphometric analysis
UW HTK Krebs+BDM HTK+BDM
Donor weight (kg) 30.3 ± 3.3 24.1 ± 1.9 28.6 ± 4.6 25.6 ± 1.0
Recipient weight (kg) 42.3 ± 5.3 34.9 ± 2.7 38.6 ± 3.5 33.2 ± 2.2
Total heart weight (g) 119.1 ± 11.4 104.7 ± 11.4 135.7 ± 19.9 104.7 ± 6.4
RV free wall (g) 31.1 ± 3.2 27.9 ± 4.3 37.0 ± 7.9 29.2 ± 3.4
LV free wall (g) 54.4 ± 9.0 49.6 ± 4.7 67.3 ± 10.4 51.2 ± 4.4
Interventricular septum (g) 33.6 ± 10.8 27.2 ± 3.9 31.4 ± 6.2 24.3 ± 2.7
Mean values ± SD are given for University of Wisconsin (UW, n = 6), Bretschneider’s HTK (HTK, n = 6), BDM in Krebs solution (Krebs+BDM, n = 7), and
BDM in Bretschneider’s HTK (HTK+BDM, n = 6) groups. Differences among groups were not statistically significant.
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Results
RV Balloon Volume
Results of heart morphometric analyses are summarized in
Table 1. As illustrated in Figure 2, A, the RV could be
loaded with significantly more volume in the Krebs+BDM
and HTK+BDM groups than in the HTK control group after
1 hour of reperfusion before the onset of RV failure.
Although RV load in the UW control group was less than
that in BDM-treated groups, this difference was not statisti-
cally significant (41.7 ± 13.3 mL [UW] vs 31.7 ± 11.7 mL
[HTK] vs 55.7 ± 14.0 mL [Krebs+BDM] vs 61.7 ± 9.8 mL
HTK+BDM; P = .002). The same observations could be
seen after 2 hours of reperfusion (56.7 ± 10.3 mL [UW] vs
43.3 ± 8.2 mL [HTK] vs 70.0 ± 10.0 mL [Krebs+BDM] vs
66.7 ± 15.1 mL [HTK+BDM]; P = .002; Figure 2, B). After
reperfusion, RV volume, measured at maximum RV devel-
oped pressure, increased in all groups (1 hour vs 2 hours of
reperfusion; P < .05). 
RV Developed Pressure
There was no significant difference in maximum RV devel-
oped pressure among groups after 1 hour of reperfusion (P
= .063; Figure 3, A). After 2 hours, maximum RV developed
pressure was significantly higher in HTK-, Krebs+BDM-,
and HTK+BDM-treated groups as compared with UW-
treated control animals (P = .04; Figure 3, B). 
RV Diastolic Pressure-volume Relationship
RV diastolic compliance was calculated at maximum RV
balloon developed pressure before the onset of RV failure.
Krebs+BDM and HTK+BDM animals revealed signifi-
cantly higher RV diastolic compliance than did UW and
HTK controls both after 1 hour (P = .02; Figure 4, A) and
after 2 hours of reperfusion (P = .039; Figure 4, B).
Whereas the Krebs+BDM group and the BDM+HTK group
did not differ with respect to RV diastolic compliance after
1 hour of reperfusion, after 2 hours of reperfusion
Figure 2. Maximum right ventricular (RV) balloon volume before
onset of RV failure in milliliters after 1 hour (A) and after 2 hours
of reperfusion (B). Mean values ± SD are given for University of
Wisconsin (UW, n = 6), Bretschneider’s HTK (HTK, n = 6), BDM in
Krebs solution (Krebs+BDM, n = 7), and BDM in Bretschneider’s
HTK (HTK+BDM, n = 6) groups. *Statistically significant differ-
ences between HTK and Krebs+BDM and between HTK and
HTK+BDM groups (ANOVA with Bonferroni’s post hoc test).
Figure 3. Maximum developed right ventricular (RV) pressure
before onset of RV failure in millimeters of mercury after 1 hour (A)
and after 2 hours of reperfusion (B). Mean values ± SD are given
for University of Wisconsin (UW, n = 6), Bretschneider’s HTK (HTK,
n = 6), BDM in Krebs solution (Krebs+BDM, n = 7), and BDM in
Bretschneider’s HTK (HTK+BDM, n = 6) groups. *Statistically sig-
nificant difference among UW and HTK, Krebs+BDM, and
HTK+BDM groups (ANOVA).
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BDM+HTK animals showed markedly, although not signif-
icantly, higher values than Krebs+BDM animals.
RV end-diastolic pressure-volume curves for RV balloon
volumes from 0 to 80 mL show significantly decreased
diastolic pressures in BDM-treated groups after 1 hour (P =
.02; Figure 5, A) and after 2 hours of reperfusion (P < .001;
Figure 5, B).
RV dP/dt
The RV dP/dt, obtained at maximum RV developed pres-
sure, increased in all groups between 1 and 2 hours of reper-
fusion except for the HTK+BDM group, which was already
showing high values after 1 hour (Table 2). Differences
among groups or between 1 hour and 2 hours of reperfusion
were not statistically significant. 
Blood Parameters
Serum CK activity and CK-MB concentration increased 10-
to 100-fold during the experiment. Lactate levels increased
10-fold. No statistically significant differences among
groups were observed with respect to serum CK activity,
CK-MB concentration, or lactate levels. Troponin-T serum
levels increased more than 100-fold from before surgery to
2 hours after reperfusion. Troponin-T levels after 2 hours of
reperfusion were significantly lower in both BDM-treated
groups than in the UW group (P = .02, Table 2).
Discussion
The addition of the calcium-desensitizing agent BDM to
cardioplegic solutions resulted in a significant improvement
of postischemic RV function in this study. Our protocol was
designed to especially address the question of RV postis-
chemic function, which remains a critical issue in clinical
heart and heart-lung transplantation.
BDM is an effective inhibitor of skeletal and cardiac
muscle contraction.5 Several mechanisms for its action have
Figure 4. Right ventricular (RV) diastolic compliance at maximum
volume load before onset of RV failure in millimeters per millime-
ter of mercury after 1 hour (A) and after 2 hours of reperfusion (B).
Mean values ± SD are given for University of Wisconsin (UW, n =
6), Bretschneider’s HTK (HTK, n = 6), BDM in Krebs solution
(Krebs+BDM, n = 7), and BDM in Bretschneider’s HTK (HTK+BDM,
n = 6) groups. *Statistically significant differences among groups
after 1 and 2 hours of reperfusion (ANOVA).
Figure 5. Right ventricular (RV) end-diastolic pressure-volume
relationship for RV balloon volume increments from 0 to 80 mL
after 1 hour (A) and after 2 hours of reperfusion (B). Mean values
± SEM are given for University of Wisconsin (UW, n = 6),
Bretschneider’s HTK (HTK, n = 6), BDM in Krebs solution
(Krebs+BDM, n = 6), and BDM in Bretschneider’s HTK (HTK+BDM,
n = 6) groups. *Statistically significant difference (P = .02,
repeated-measures ANOVA; A) between HTK and BDM+HTK
groups as determined by Bonferroni’s post hoc test. *Statistically
significant difference (P < .001, repeated-measures ANOVA; B)
among both control groups and both BDM-treated groups as
determined by Bonferroni’s post hoc test.
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been suggested. A direct modulation of cross-bridge inter-
action on the level of the intracellular contractile apparatus
has been reported by a number of investigators in rat,13,14
guinea pig,15 and human cardiac muscle.16 Within this
model, BDM exerts negative inotropic effects by reducing
the number of force-generating cross-bridges by increasing
the cross-bridge detachment rate as well as by reducing
force generation per cross-bridge.15,16 Other studies focus
on the effect of BDM on sarcoplasmic reticulum Ca2+ han-
dling.17-19 This can be described as a Ca2+-desensitizing
effect and has been observed in both cardiac and skeletal
skinned muscle fibers.20 Originally, BDM was described as
a nucleophilic oxime with a phosphatase-like activity21 and
has also been shown to inhibit actomyosin adenosine-
triphosphatase.14,22,23 Yet, the exact effect of BDM on
myocardial adenosinetriphosphatase activity and energy
demand still needs to be determined. A cardioprotective
effect of BDM has been questioned on theoretical grounds,
because BDM leads to an increase in myocardial tension
cost, that is, the ratio of adenosinetriphosphatase activity
versus (developed) muscle tension,16 thus increasing
adenosinetriphosphate usage per developed tension.
In contrast to these theoretical considerations, there is
strong evidence from various experimental settings that
adjunctive application of BDM to cardioplegic solutions is
beneficial.4,10,11 Contraction uncoupling during initial
postischemic reperfusion by BDM has been equally effec-
tive when applied over a 20-minute period in a dosage of 20
mmol/L.9 The drug is fast acting and its effects are fully
reversible within minutes.8,9 This is at variance to slow
channel calcium antagonists like nifedipine or diltiazem,
which may be disadvantageous in practical clinical terms
because of an overhanging cardiodepressant effect.24 In our
study, the use of BDM was restricted to the ischemic period
to prevent systemic side effects during reperfusion. No dis-
cussion of BDM as a cardioplegic agent in a large animal
model of transplantation has been published to date.
A number of investigators previously reported on
improved parameters of LV function after cardioplegia with
BDM in models of rat heart ischemia and reperfusion in a
Langendorff preparation.6-8 Extrapolation of results from
experiments in rat hearts related to calcium metabolism,
however, is probably not feasible because calcium metabo-
lism might differ between rats and other mammals.25
Therefore, results need to be corroborated in a species com-
parable with human calcium metabolism, with the pig as an
acceptable model. Above that, the question of RV protec-
tion and recovery has not been addressed in those studies.
The isovolumic model selected for this study enables
control of the effects of confounding variables for right
heart function and compensation mechanisms in right heart
failure. Although it does not exactly mimic the clinical sit-
uation, the complexity of RV hemodynamics and associated
determinants provided the rationale for its use. The isovolu-
mic preparation used in this study permitted precise control
of RV volume. Because left heart hemodynamics influence
maximum RV developed pressure,26 observations in this
study were made under conditions of controlled, constant
left heart hemodynamics, with constant left heart output and
systolic LV (and hence, aortic) pressure. Thus, the present
model allowed optimal control of potential variables that
may influence data obtained on RV function. Pulmonary
vascular resistance is a very inconsistent parameter in mod-
els of orthotopic heart transplantation. This problem was
avoided in the isovolumic right heart preparation used in
this study. During measurements the RV is subjected to
increasing balloon volumes, and thereby increasing after-
load, inasmuch as the volume is not ejected. However, one
TABLE 2. RV dP/dt and CK-MB and troponin-T blood levels
UW HTK Krebs+BDM HTK+BDM
RV dP/dt (mm Hg/s2) 1: 4041 ± 1675 1: 4920 ± 731 1: 5370 ± 1581 1: 5440 ± 2039
2: 4385 ± 1382 2: 7464 ± 3540 2: 5862 ± 1288 2: 4789 ± 657
Plasma CK-MB concentration (µg/L) 1: 6.3 ± 3.4 1: 6.5 ± 2.3 1: 5.0 ± 1.3 1: 6.0 ± 2.7
2: 53.4 ± 25.1 2: 44.3 ± 7.2 2: 66.1 ± 23.9 2: 50.4 ± 18.5
3: 93.1 ± 26.8 3: 92.1 ± 34.0 3: 113.3 ± 33.7 3: 76.6 ± 16.6
4: 98.4 ± 25.7 4: 121.0 ± 47.2 4: 134.7 ± 49.2 4: 93.8 ± 25.4
Plasma troponin-T levels (µg/L) 1: 0.05 ± 0.09 1: 0.2 ± 0.4 1: 0.04 ± 0.09 1: 0.01 ± 0.0
2: 4.3 ± 4.3* 2: 1.4 ± 0.7 2: 1.2 ± 0.6 2: 1.0 ± 0.3
3: 10.3 ± 5.6* 3: 5.7 ± 3.0 3: 5.8 ± 3.5 3: 4.2 ± 2.1
4: 11.7 ± 6.1* 4: 6.4 ± 2.8 4: 5.3 ± 2.6 4: 5.1 ± 1.6
Right ventricular (RV) dP/dt and blood levels of markers of myocardial injury. Mean values ± SD are given for University of Wisconsin (UW, n = 6),
Bretschneider’s HTK (HTK, n = 6), BDM in Krebs solution (Krebs+BDM, n = 7), and BDM in Bretschneider’s HTK (HTK+BDM, n = 6) groups. RV dP/dt was
recorded after 1 hour (1) and 2 hours (2) of reperfusion. Serum for creatine kinase MB (CK-MB) concentrations in micrograms per liter and troponin-T lev-
els in micrograms per liter was collected before surgery from an arterial line (1) and after 10 minutes (2), 60 minutes (3), and 120 minutes (4) of reperfu-
sion from the coronary sinus.
*Statistically significant difference between UW and BDM-treated groups (P = .049, P = .05, and P = .02, respectively; ANOVA).
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limitation of the model is the condition of RV afterload dur-
ing the remainder of the reperfusion period. With the bal-
loon empty, effective RV afterload is low. Additionally, LV
output was restricted to 200 mL/min and LV afterload was
adjusted to 60 mm Hg. Thus, the total load for the trans-
planted heart was relatively low. Although this might be dif-
ferent from the clinical situation of early reperfusion after
heart transplantation, it provided the advantage that no
inotropic support was necessary.
Previous studies27 have shown that improved RV func-
tion does not necessarily have to be expressed as increased
RV pressure. The RV may also react with increased volume
load at constant pressures. In our study, there was an
increase in maximum developed RV pressure after addition
of BDM to HTK solution, as well as an increase in RV bal-
loon volume at maximum RV developed pressure of up to
30 mL in BDM-treated animals as compared with UW or
HTK control animals. A 10-mL increase in RV volume
would mean that the RV, paced at a rate of 130 beats/min,
could “pump” 1.3 L of volume more per minute after BDM
protection. UW control animals showed the lowest postis-
chemic maximum developed RV pressures; HTK control
animals showed good developed RV pressures but the low-
est postischemic RV volume load. The good developed RV
pressures in the HTK group, however, were recorded at
much lower volumes, indicating well-maintained myocar-
dial contractility but impaired compliance of the RV. This
finding is strengthened by equally high diastolic pressures
in HTK and UW animals on analysis of end-diastolic RV
pressure-volume relationships and by the low RV compli-
ance at maximum volume load in both the HTK and the
UW group. Both BDM-treated groups show markedly
improved RV diastolic properties by decreased RV diastolic
pressures and thus increased RV compliance at maximum
volume load, this well preserved RV compliance being a
prerequisite for effective ventricular work.28
The improved protection from ischemia-reperfusion
injury in BDM animals was confirmed by a significantly
lower release of troponin-T in BDM-treated groups after 2
hours of reperfusion. In our experimental model, CK-MB
serum concentrations increased continuously with time in
all groups, and after reperfusion HTK+BDM animals
showed the lowest concentrations. CK activity did not dif-
fer significantly among groups, with a possible explanation
being the ligation of the femoral arteries for cannulation,
causing an increased lactate and CK release from the pigs’
lower extremities.
Although differences in the functional recovery of hearts
and in the release of markers of tissue injury were not sta-
tistically significant between BDM in Krebs solution and
BDM in HTK, BDM in HTK seems to provide superior
preservation, as is shown by slightly better postischemic
function and lower tissue injury marker release. However,
the good functional recovery of hearts preserved with BDM
in Krebs solution as compared with BDM in HTK was not
expected and provides additional evidence for the excellent
preservation properties of that agent.
The calcium concentration of a heart preservation solu-
tion has been reported to have an important influence on
postischemic myocardial function.29 All preservation solu-
tions used in this study have varying calcium concentrations
and, above that, BDM is known to chelate free ionized cal-
cium in a dose-dependent manner.30 At 30 mmol/L, BDM
reduces ionized free calcium by 50%. Robinson and
Harwood29 reported that reducing the calcium concentra-
tion in St Thomas’ Hospital solution from 1.2 to 0.6
mmol/L results in a significant improvement of recovery of
postischemic function in rat hearts. Comparing the solu-
tions used in our study, UW solution contains no calcium at
all and the calcium concentration of HTK (0.015 mmol/L)
is low. Although one could speculate that these low calcium
concentrations might have caused part of the difference in
RV function as compared with the BDM groups, this is
unlikely considering the fact that the addition of BDM to
HTK, which resulted in a significant improvement of RV
function, should even lower its calcium concentration. On
the other hand, it is not possible to conclude that relatively
high calcium concentrations per se are deleterious, because
BDM also provided significantly improved RV protection
on addition to Krebs-Henseleit solution with a calcium con-
centration of 2.5 mmol/L (that should have been reduced by
chelating to 1.25 mmol/L by BDM). However, the exact
contribution of calcium concentration to RV protection in
the solutions investigated in this study still needs to be
determined.
In conclusion, our study demonstrates that RV function
after transplantation is significantly improved after addition
of BDM to HTK solution. Using an isovolumic right heart
transplant preparation with total control of LV function,
maximum volume load of the RV before the onset of RV
failure was significantly higher and end-diastolic RV pres-
sure was significantly lower after BDM application than in
controls with HTK alone. Thus, administration of BDM-
supplemented cardioplegic solution may protect the
myocardium from ischemic injury after prolonged ischemia
during transplantation. 
We thank Adine Timke, Astrid Diers-Ketterkatt, Petra Ziehme,
Rosie Katt, Karin Peschel, and Jost Dörr for their invaluable tech-
nical assistance. 
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